PHAT Stock Analysis: Buy, Sell, or Hold?
PHAT - Phathom Pharmaceuticals, Inc. Common Stock
$8.87
0.27 (3.14%)
▲
5d:
-7.41%
30d:
-23.53%
90d:
-23.4%
HOLD
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When PHAT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PHAT is fairly valued with market pricing in 1.8% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: PHAT is fairly valued with market pricing in 1.8% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$11.82
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$7.34
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAT is currently trading at $8.87, which is considered oversold relative to its 30-day fair value range of $8.69 to $11.22. The stock's valuation (Forward PE: 8.0) is in line with its historical norms (7.6). At these levels, the market is pricing in 1.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PHAT is in a strong downtrend. Immediate support is located at $8.40, while resistance sits at $9.74. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: PHAT scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $21.50 (+142.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PHAT is in a strong downtrend. Immediate support is located at $8.40, while resistance sits at $9.74. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: PHAT scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $21.50 (+142.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.69 -
$11.22
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
96.2%
Protect Your Profits
Holding PHAT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (69/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BULLISH: Trading 142.4% below Wall St target ($21.50)
- NEUTRAL: Market pricing in 1.8% annual earnings growth - fairly valued
- CAUTION: Bottoming setup, but lagging the sector by 22% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-7.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$8.69 -
$11.22
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$8.40
Resistance Level
$9.75
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.99
Wall Street Target
$21.50
(+142.4%)
Revenue Growth (YoY)
88.0%
Profit Margin
-41.3%
Valuation Premium vs History
+1.8% premium
PE vs Historical
8.0 vs 7.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.8%
(market-implied from PE analysis)
1-Year Target
$9.03
(+2%)
2-Year Target
$9.19
(+4%)
3-Year Target
$9.36
(+6%)
3-Yr Target (if PE normalizes)
(PE: 8→8)
PE COMPRESSION
$8.90
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 23, 2026 5:21 PM ET
Data refreshes hourly during market hours. Next update: 6:21 PM
Data refreshes hourly during market hours. Next update: 6:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 43 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 39 SELL |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
Advanced PHAT Option Strategies
Professional options setups generated by AI based on today's PHAT price and gamma walls.
